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A bs tr ac t
Background
Transplant recipients in whom cutaneous squamous-cell carcinomas develop are at 
high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the 
prevention of secondary skin cancer has not been assessed.
Methods
In this multicenter trial, we randomly assigned transplant recipients who were tak-
ing calcineurin inhibitors and had at least one cutaneous squamous-cell carcinoma 
either to receive sirolimus as a substitute for calcineurin inhibitors (in 64 patients) 
or to maintain their initial treatment (in 56). The primary end point was survival 
free of squamous-cell carcinoma at 2 years. Secondary end points included the time 
until the onset of new squamous-cell carcinomas, occurrence of other skin tumors, 
graft function, and problems with sirolimus.
Results
Survival free of cutaneous squamous-cell carcinoma was significantly longer in the 
sirolimus group than in the calcineurin-inhibitor group. Overall, new squamous-cell 
carcinomas developed in 14 patients (22%) in the sirolimus group (6 after with-
drawal of sirolimus) and in 22 (39%) in the calcineurin-inhibitor group (median 
time until onset, 15 vs. 7 months; P = 0.02), with a relative risk in the sirolimus 
group of 0.56 (95% confidence interval, 0.32 to 0.98). There were 60 serious adverse 
events in the sirolimus group, as compared with 14 such events in the calcineurin-
inhibitor group (average, 0.938 vs. 0.250). There were twice as many serious adverse 
events in patients who had been converted to sirolimus with rapid protocols as in 
those with progressive protocols. In the sirolimus group, 23% of patients discon-
tinued the drug because of adverse events. Graft function remained stable in the 
two study groups.
Conclusions
Switching from calcineurin inhibitors to sirolimus had an antitumoral effect among 
kidney-transplant recipients with previous squamous-cell carcinoma. These obser-
vations may have implications concerning immunosuppressive treatment of pa-
tients with cutaneous squamous-cell carcinomas. (Funded by Hospices Civils de 
Lyon and others; TUMORAPA ClinicalTrials.gov number, NCT00133887.)
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Skin cancers affect more than half of organ-transplant recipients during their long-term course.1 Several studies have 
shown that after a first cutaneous squamous-cell 
carcinoma, multiple subsequent skin cancers de-
velop in 60 to 80% of kidney-transplant recipients 
within 3 years.2,3 Transplant recipients share com-
mon risk factors with the nonimmunosuppressed 
population,4 but the specific tumor burden of such 
patients is linked to the immunosuppressive med-
ications used.5,6 A decrease in cutaneous carcino-
genesis after the reduction of immunosuppres-
sion has been reported.7 Consequently, changes in 
immunosuppression are frequently made in patients 
with skin cancer, although there is currently no 
consensus on the level of morbidity at which this 
decision is justified.8 Cutaneous squamous-cell 
carcinoma appears to be one of the most appro-
priate markers for initiating a change in immuno-
suppressive medication for organ-transplant re-
cipients and subsequently for assessing the effect 
of such changes on carcinogenesis according to 
skin-tumor counts.
Skin cancers result from both a decrease in im-
munosurveillance and drug-specific properties. 
Calcineurin inhibitors (cyclosporine and tacroli-
mus) may enhance tumor development through 
mechanisms independent of host immunity.9-12 In 
contrast, inhibitors of the mammalian target of 
rapamycin (mTOR), including sirolimus (Rapa-
mune, Pfizer) and everolimus, are newer immu-
nosuppressants that have antineoplastic proper-
ties.13,14 A few studies have reported a lower rate 
of skin cancer in transplant recipients who were 
treated with sirolimus than in those treated with 
calcineurin inhibitors (with either first-time ther-
apy15,16 or after switching17,18), but data focusing 
on the effect of sirolimus on skin carcinomas are 
still limited.19,20 The aim of our study, called the 
Efficacy of Rapamycin in Secondary Prevention 
of Skin Cancers in Kidney Transplant Recipients 
(TUMORAPA), was to assess, in a large cohort, 
the efficacy of sirolimus for the secondary pre-
vention of skin cancers in kidney-transplant re-
cipients receiving calcineurin inhibitors.
Me thods
Eligibility
Kidney-transplant recipients with stable kidney 
function who were receiving calcineurin inhibi-
tors and had at least one invasive post-transplant 
cutaneous squamous-cell carcinoma after trans-
plantation were eligible to participate. (Patients 
with in situ lesions, such as Bowen’s disease and 
premalignant keratosis, or metastatic cutaneous 
squamous-cell carcinomas were not considered.) 
The major exclusion criteria were multiorgan trans-
plantations, a history of organ rejection during the 
past 6 months, poor graft function (estimated glo-
merular filtration rate, <30 ml per minute, accord-
ing to the Cockcroft–Gault formula; or 24-hour 
protein excretion of >1 g), uncontrolled hyperlip-
idemia, hematologic or hepatic disorders, and 
retinoid treatment. The limits on baseline immu-
nosuppressant doses were as follows: glucocorti-
coids, 10 mg or less per day; azathioprine, 1 mg or 
less per kilogram of body weight per day; myco-
phenolate mofetil, 1.5 g or less per day; and target 
cyclosporine and tacrolimus blood trough levels, 
75 to 125 ng per milliliter and 4 to 7 ng per milli-
liter, respectively.
Trial Design
This phase 3, multicenter, randomized, open-label 
trial included patients who had had a first cuta-
neous squamous-cell carcinoma (TUMORAPA-1, 
which was registered under ClinicalTrials.gov 
number NCT00133887 in March 2004 and under 
EUDRACT 2004-004947-23) and those with mul-
tiple squamous-cell carcinomas (TUMORAPA-N, 
registered under EUDRACT 2005-004509-27). The 
study was conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice 
guidelines and was approved by the local re-
search ethics committee (TUMORAPA-1 on Febru-
ary 23, 2004, and TUMORAPA-N on June 1, 2004) 
and the French Health Products Safety Agency. 
All patients received a detailed description of the 
study and provided written informed consent. 
The full study protocol, including the statistical 
analysis plan, is available with the full text of this 
article at NEJM.org.
Randomization and Treatment
Patients were randomly assigned in a 1:1 ratio 
either to transition to sirolimus from calcineurin 
inhibitors or to continue receiving calcineurin in-
hibitors. In the sirolimus group, calcineurin inhibi-
tors were discontinued and sirolimus was added 
to the usual immunosuppressive agents, accord-
ing to the routine practice of each center (target 
trough level of sirolimus, 6 to 12 ng per milli-
liter). The conversion to sirolimus was considered 
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to be rapid if calcineurin inhibitors were discon-
tinued within 7 days and progressive if the conver-
sion took longer than 7 days. In the calcineurin-
inhibitor group, cyclosporine and tacrolimus were 
maintained at their previous target trough levels.
Study Evaluations
All patients were examined by a dermatologist and 
a nephrologist at enrollment and every 3 months 
thereafter until the 2-year mark. During the der-
matologic examination, investigators recorded 
skin type according to Fitzpatrick’s classification 
(Table 1 in the Supplementary Appendix, available 
at NEJM.org), eye and hair color, and sun exposure. 
Sun exposure was scored on the basis of occupa-
tional and leisure exposure (1, low; 2, medium; 
and 3, high), tanning-bed use (1, never; 2, occa-
sional; and 3, regular), and residence of more than 
6 months in a tropical area (1, no; and 2, yes). All 
histologically determined skin tumors (including 
squamous- and basal-cell carcinoma, keratoac-
anthoma, Bowen’s disease, premalignant keratosis, 
and other rare cancers) before and after random-
ization were counted. Sun-protection advice was 
provided and its importance was emphasized.
During visits to the nephrology or transplan-
tation clinic at each center, doses of immunosup-
pressive medications were recorded, along with 
the patient’s history of acute organ rejection. For 
patients who had undergone more than one trans-
plantation, the duration of immunosuppression 
was calculated by summing the number of months 
120 Underwent randomization
129 Patients underwent randomization
9 Were excluded
4 Were lost to follow-up
5 Did not meet inclusion
criteria
64 Were assigned to sirolimus group
56 Were assigned to calcineurin-inhibitor
group
5 Dropped out of study
2 Withdrew consent
3 Switched to sirolimus
group because of
cancer diagnosis
15 Dropped out of study
2 Withdrew consent
12 Had adverse events
1 Discontinued for
surgery
49 Were included in 1-yr follow-up  51 Were included in 1-yr follow-up
7 Dropped out of study
1 Was lost to follow-up
1 Died (myocardial
infarction)
5 Switched to sirolimus
group because of
cancer diagnosis
7 Dropped out of study
1 Was lost to follow-up
1 Died (heart failure)
3 Had adverse events
2 Discontinued for
surgery
42 Were included in 2-yr follow-up 44 Were included in 2-yr follow-up
Figure 1. Enrollment and Outcomes.
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of receipt of immunosuppressive drugs from the 
first transplantation and subtracting the interven-
ing duration of dialysis. At the initial nephrology 
visit, measurements of serum creatinine levels, 
24-hour protein excretion, and sirolimus or cal-
cineurin-inhibitor levels were obtained; these mea-
surements were then repeated every 3 months in 
the calcineurin-inhibitor group. In the sirolimus 
group, monitoring was carried out weekly dur-
ing the first 2 weeks, monthly during the first 
3 months, and then every 3 months.
End Points
The primary end point was survival free of new 
cutaneous squamous-cell carcinoma at 2 years. 
Secondary end points included the time until the 
onset of new cutaneous squamous-cell carcino-
ma, occurrence of other skin and nonskin tumors, 
and graft function. Safety was monitored by means 
of physical examination, the recording of adverse 
events, and changes in laboratory measurements.
Study Oversight
The manufacturer of sirolimus, Pfizer (formerly 
Wyeth), provided a research grant but had no role 
in the trial design or in the collection, analysis, 
or interpretation of the data or writing of the 
report. The study was sponsored by the Hospices 
Civils de Lyon, and grants were received from the 
French Ministry of Health, the French Society of 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Sirolimus
(N = 64)
Calcineurin Inhibitor
(N = 56)
Male sex — no. (%) 47 (73) 45 (80)
Age at inclusion — yr
Median 62 63
Range 37–84 30–76
Skin type — no. (%)†
I, II, or III 47 (73) 46 (82)
IV 17 (27) 10 (18)
Eye color — no. (%)
Black or brown 17 (27) 10 (18)
Hazel or light 47 (73) 46 (82)
Hair color — no. (%)
Black 18 (28) 14 (25)
Brown 28 (44) 27 (48)
Blond 15 (23) 12 (21)
Red 3 (5) 3 (5)
Patients with cutaneous squamous-cell carcinoma
Single lesion — no. (%) 35 (55) 31 (55)
Multiple lesions — no. (%) 29 (45) 25 (45)
Median — no. 3 3
Range — no. 2–15 2–12
Interval between diagnosis of the most recent cutaneous squamous-cell 
carcinoma and randomization — mo
Median 4.5 6.0
Range 0–43.5 0–111.1
Other nonmelanoma skin cancer — no./total no. (%) 39/63 (62) 41/55 (75)
Sun-exposure score‡
Median 7 7
Range 4–10 4–10
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Dermatology, and Pfizer. The first and last au-
thors, along with several colleagues, made the de-
cision to submit the manuscript for publication and 
vouch for the accuracy and completeness of the 
data and the fidelity of the study to the protocol.
Statistical Analysis
Since we used the same methods and end points 
that were used in both TUMORAPA-1 and 
TUMORAPA-N, the data were pooled. The analy-
sis included the total population as well as sepa-
rate analyses of patients who had had a single 
cutaneous squamous-cell carcinoma and those 
who had had more than one such lesion before 
randomization. We used the Mann–Whitney test 
for comparing quantitative variables and Fisher’s 
exact test for comparing qualitative variables. 
The main evaluation criteria were analyzed in the 
intention-to-treat population. We evaluated the 
status at 2 years for patients who had withdrawn 
from the study. Deceased patients without cuta-
neous squamous-cell carcinoma before death were 
included among patients who were free of cuta-
neous squamous-cell carcinoma.
Patients were analyzed according to the ran-
domization scheme. We used nonparametric 
maximum-likelihood estimation to analyze the 
rate of survival free of new cutaneous squamous-
cell carcinoma on the basis of interval-censored 
data.21 Since the occurrence of a new carcinoma 
was observed only quarterly because of the timing 
of visits, the actual time of the event was un-
known and survival was computed at time inter-
vals rather than at a precise times (i.e., the interval 
between the last visit at which no diagnosis of 
cutaneous squamous-cell carcinoma was made 
and the visit when the cutaneous squamous-cell 
carcinoma was first mentioned). We used the 
generalized log-rank test to compare the two 
study groups.21 Crude hazard ratios, adjusted haz-
Table 1. (Continued.)
Characteristic
Sirolimus
(N = 64)
Calcineurin Inhibitor
(N = 56)
Transplantations before randomization — no. (%)
1 48 (75) 48 (86)
≥2 16 (25) 8 (14)
Dialysis before transplantation — no. (%) 57 (89) 52 (93)
History of acute organ rejection — no./total no. (%) 15/61 (25) 12/54 (22)
Length of immunosuppression — mo
Median 148.6 142.9
Range 18.8–565.6 12.2–426.5
Creatinine — µmol/liter
Median 123 116
Range 61–237 74–241
Estimated glomerular filtration rate — ml/min§
Median 52.8 50.6
Range 27.3–135.5 31.9–111.2
24-Hr protein excretion — g
Median 0.10 0.10
Range 0–0.98 0–0.73
* There were no significant differences between the two study groups. Percentages may not total 100 because of rounding. 
To convert the values for creatinine to milligrams per deciliter, divide by 88.4.
† Skin type was graded according to Fitzpatrick’s classification as follows: type I, white with history of always burning and 
never tanning; type II, white with some burning and tanning with difficulty; type III, beige with occasional burning and 
gradual tanning to light brown; and type IV, beige with rare burning and tanning to moderate brown.
‡ Sun exposure was scored on the basis of occupational and leisure exposure (1, low; 2, medium; and 3, high), tanning-bed 
use (1, never; 2, occasional; and 3, regular), and residence of more than 6 months in a tropical area (1, no; and 2, yes).
§ The estimated glomerular filtration rate was calculated by means of the Cockcroft–Gault formula.
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ard ratios, and tests for interaction were obtained 
with the use of an accelerated failure-time model 
with interval censoring. In order to assess the 
benefit–risk balance, we counted the numbers of 
cutaneous squamous-cell carcinomas and treat-
ment-related serious adverse events during the 
therapy period and for 3 months after the dis-
continuation of treatment. We performed sec-
ondary evaluations of patients who completed the 
2-year treatment to which they were initially as-
signed. Analyses were performed with the use of 
SAS software, version 9.2. A two-sided P value of 
less than 0.05 was considered to indicate statis-
tical significance.
R esult s
Patients
From March 2004 through March 2009, we en-
rolled 129 patients in the study; of these patients, 
120 were included in the primary analysis (Fig. 1). 
The demographic characteristics of the patients 
at baseline were well balanced between the two 
study groups (Table 1). At baseline, 290 cutaneous 
squamous-cell carcinomas had been diagnosed 
in 120 patients; of these patients, 55% had a sin-
gle lesion, and the remainder had multiple lesions 
(average number, 4.2; range, 2 to 15). In addition, 
68% of the patients had a total of 274 other biop-
sy-proven skin tumors (68 basal-cell carcinomas, 
27 keratoacanthomas, 90 in situ carcinomas [or 
Bowen’s disease], and 89 premalignant keratoses). 
Because of empirical treatments (e.g., cryotherapy), 
some superficial premalignant lesions were not 
examined histologically, which may account for 
the low number of these lesions, as compared with 
invasive cutaneous squamous-cell carcinomas. A 
total of 84 patients were receiving cyclosporine, 
and 36 were receiving tacrolimus, with mean 
trough levels of 90.6±33.0 ng per milliliter and 
6.9±2.2 ng per milliliter, respectively (Table 2 in 
the Supplementary Appendix).
Primary End Point
Survival free of cutaneous squamous-cell carcino-
ma was significantly longer in the sirolimus group 
than in the calcineurin-inhibitor group, with a 
hazard ratio for new carcinoma of 0.37 (95% con-
fidence interval [CI], 0.16 to 0.85) and a study-ad-
justed hazard ratio of 0.38 (95% CI, 0.17 to 0.84) 
(Fig. 2A). This difference remained significant for 
the patients with a single cutaneous squamous-
cell carcinoma (hazard ratio, 0.03; 95% CI, 0.0 to 
0.91) but not for those with more than one cutane-
ous squamous-cell carcinoma (hazard ratio, 0.67; 
95% CI, 0.29 to 1.54) (Fig. 2B and 2C).
The effect of sirolimus was not significantly 
different between the two studies (P = 0.054 for 
interaction between study and treatment group). 
Overall, new cutaneous squamous-cell carcino-
mas developed in 14 patients (22%) in the siro-
limus group and in 22 (39%) in the calcineurin-
inhibitor group (relative risk, 0.56; 95% CI, 0.32 
to 0.98) after a median interval of 15 months, as 
compared with 7 months (P = 0.02). Among the 
patients in the sirolimus group who presented 
with new cutaneous squamous-cell carcinomas, 
lesions developed in 6 patients after sirolimus 
withdrawal, with a maximum exposure to siro-
limus of 4.1 months. The sex ratio of patients 
with new lesions was similar to that in the ini-
tial population. The clinicopathologic character-
istics of new cutaneous squamous-cell carcino-
mas are shown in Table 3 in the Supplementary 
Appendix.
Of 86 patients who completed the 2-year treat-
ment, skin cancers that included squamous-cell 
carcinomas developed in 20 patients (with 71 le-
sions) in the sirolimus group and in 31 patients 
(with 191 lesions) in the calcineurin-inhibitor 
group (47.6% vs. 70.5%, P = 0.048). During the 
study period, the ratio of squamous-cell carcino-
ma to basal-cell carcinoma decreased from 3.9 
(27 to 7) to 1.4 (11 to 8) in the sirolimus group 
and from 1.8 (21 to 12) to 1.0 (25 to 26) in the 
calcineurin-inhibitor group, as compared with 
the 2-year period preceding randomization.
Seven patients (including five in the sirolimus 
group) had a prestudy history of noncutaneous 
cancer; none of these patients had a relapse dur-
ing the study. Six noncutaneous cancers were 
observed in patients with no previous history of 
solid-organ cancer; two lung cancers had a meta-
static course (Table 2).
No episodes of graft rejection occurred during 
the study (Fig. 1 in the Supplementary Appendix). 
Trough levels of calcineurin inhibitors and siro-
limus remained within the target range of the 
study (Fig. 2 in the Supplementary Appendix). The 
average sirolimus levels at 9 months were not 
significantly higher in patients with new cutane-
ous squamous-cell carcinomas than those with-
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out such lesions (9.66 vs. 8.01 ng per milliliter, 
P = 0.08). A decrease in or discontinuation of im-
munosuppressive agents occurred in 15 of 42 pa-
tients (36%) in the sirolimus group and 13 of 44 
patients (30%) in the calcineurin-inhibitor group.
Adverse Events
Almost all sirolimus-treated patients had at least 
one adverse event that was considered to be re-
lated to the study drug (Table 3, and Table S4 in 
the Supplementary Appendix). Most such events 
occurred during the first 6 months of the study. 
A lower sirolimus dose or complementary spe-
cific treatments controlled most of them. Ad-
verse events in the sirolimus group led to discon-
tinuations in 15 patients (23%) after a median of 
2.5 months.
Overall, 37 of 64 patients were converted to 
sirolimus with rapid protocols; these patients 
had a higher rate of discontinuation than did 
those who were converted with progressive pro-
tocols (11 of 37 patients [30%] vs. 4 of 27 pa-
tients [15%], P = 0.24), as well as higher rates of 
pneumonitis (11 of 37 patients [30%] vs. 3 of 27 
patients [11%], P = 0.13) and serious adverse 
events (24 of 37 patients [65%] vs. 8 of 27 pa-
tients [30%], P = 0.01).
Metastatic cutaneous squamous-cell carcinoma 
developed in one patient in the sirolimus group; 
this patient had received sirolimus for 2 months 
and was then switched back to calcineurin in-
hibitors. The metastasis occurred 6 months after 
the conversion. Eight patients in the calcineurin-
inhibitor group were switched to sirolimus after 
the development of other cancers (Table 3). Meta-
static skin cancers (one case each of squamous-
cell carcinoma, melanoma, and Merkel-cell carci-
noma) developed in three patients.
Among the 120 patients, there were 13 cuta-
neous squamous-cell carcinomas in 64 patients 
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Figure 2. Probability of Survival Free of New Cutaneous 
Squamous-Cell Carcinoma at 2 Years.
Shown are probability curves for the primary outcome 
(survival free of new cutaneous squamous-cell carcino-
ma) among patients in the intention-to-treat population 
(Panel A), among those with a single cutaneous squa-
mous-cell carcinoma before randomization (Panel B), 
and among those with more than one cutaneous squa-
mous-cell carcinoma before randomization (Panel C). 
The shaded boxes indicate 95% confidence intervals.
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(average number, 0.20) in the sirolimus group, 
as compared with 39 carcinomas in 56 patients 
(average number, 0.70) in the calcineurin-inhibitor 
group. In the sirolimus group, there were 60 seri-
ous adverse events (average number, 0.94), as com-
pared with 14 (average number, 0.25) in the 
calcineurin-inhibitor group (Table 3).
Discussion
In this study of kidney-transplant recipients with 
at least one previous cutaneous squamous-cell 
carcinoma, switching from calcineurin inhibi-
tors to sirolimus decreased the risk of new cuta-
neous squamous-cell carcinomas and delayed the 
Table 2. Dermatologic Results.*
Variable Sirolimus Calcineurin Inhibitor P Value†
Secondary outcome‡
No. of patients evaluated 42 44
Patients with at least one new nonmelanoma 
skin cancer — no. (%)
16 (38) 28 (64) 0.03
New skin tumors other than squamous-cell  
carcinoma — no.
60 164
Mean 3.8±3.6 5.9±6.5 0.47
Median (range) 2.5 (1–13) 3 (1–22)
Patients with a single cutaneous squamous-cell  
carcinoma before randomization
No. of patients evaluated 24 25
Patients with at least one new nonmelanoma 
skin cancer — no. (%)
9 (38) 15 (60) 0.02
New skin tumors other than squamous-cell  
carcinoma — no.
29 53
Mean 3.2±2.8 3.5±5.5 0.54
Median (range) 3 (1–9) 1 (1–22)
Patients with several cutaneous squamous-cell  
carcinomas before randomization
No. of patients evaluated 18 19
Patients with at least one new nonmelanoma 
skin cancer — no. (%)
7 (39) 13 (68) 0.10
New skin tumors other than squamous-cell  
carcinoma — no.
31 111
Mean 4.4±4.5 8.5±6.9 0.15
Median (range) 2 (1–13) 8 (1–20)
Incidence of new skin tumors other than  
squamous-cell carcinoma
1.43 3.73
No. of patients evaluated 42 44
At least one basal-cell carcinoma — no. (%) 6 (14) 12 (27) 0.19
At least one keratoacanthoma — no. (%) 3 (7) 9 (20) 0.12
At least one Bowen’s disease — no. (%) 4 (10) 6 (14) 0.74
At least one premalignant keratosis — no. (%) 11 (26) 16 (36) 0.36
Other skin cancers — no. 0 1 Merkel-cell, 1 adnexal
Other, nonskin cancers — no. 1 colon, 1 prostate,  
1 lung
1 kidney, 1 lymphoma,  
1 lung
* Plus–minus values are means ±SD.
† P values were calculated by means of the Mann–Whitney test (for quantitative variables) or Fisher’s exact test (for qual-
itative variables).
‡ Secondary outcomes were evaluated in 86 patients who completed the 2-year treatment as initially assigned.
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occurrence of such lesions, as compared with con-
tinuing calcineurin inhibitors. Drug discontinua-
tions in the sirolimus group were mainly due to 
the known adverse effects of the drug.17,22 Al-
though serious adverse events were significantly 
more frequent (0.94 per patient) in the sirolimus 
group than in the calcineurin-inhibitor group (0.25 
per patient), the number of cutaneous squamous-
cell carcinomas was lower by a factor of 3.4.
The benefit–risk ratio appeared to increase with 
lower doses of sirolimus (as compared with higher 
doses) and with progressive conversion from 
calcineurin inhibitors to sirolimus (as compared 
with rapid conversion). This apparent antitumoral 
effect was more pronounced when sirolimus was 
introduced after the first occurrence of a cutane-
ous squamous-cell carcinoma, as compared with 
introduction after the occurrence of multiple cu-
taneous squamous-cell carcinomas. Furthermore, 
the ratio of squamous-cell carcinoma to basal-cell 
carcinoma decreased substantially in the siroli-
mus group; a decrease was also observed in the 
calcineurin-inhibitor group, albeit in a lower pro-
portion of patients, possibly because of the close 
follow-up, which ensured the removal of prema-
lignant lesions before they became invasive.
All metastases of skin cancers occurred in pa-
tients who were receiving calcineurin inhibitors, 
either initially (in three patients) or after switch-
ing back to calcineurin inhibitors after being as-
signed to the sirolimus group (in one patient). At 
baseline, the study population was representative 
of kidney-transplant recipients with a ratio of 
squamous-cell carcinoma to basal-cell carcinoma 
of 4. In addition, the rate of new skin cancers at 
2 years in the calcineurin-inhibitor group was 
similar to that in previous studies.2,3
Although we did not observe any significant 
between-group difference in the rate of noncuta-
neous cancers, the study was inadequately pow-
ered to draw conclusions on this point. Studies 
that have reported a reduced cancer risk with 
sirolimus-based immunosuppression that was 
initiated at the time of transplantation or after 
early cyclosporine withdrawal have mainly com-
pared regimens with two versus three immuno-
suppressive agents23 or have compared outcomes 
with registry data.15,16 Furthermore, reduced rates 
of cancer after conversion from calcineurin in-
hibitors to sirolimus were driven by skin cancers 
rather than other cancers.17,18
We speculate that there may be a specific 
antineoplastic activity of sirolimus that explains 
the decrease in new skin cancers rather than a 
lower amount of immunosuppression. Although 
no standard criteria exist to compare the levels 
of immunosuppression of calcineurin inhibitors 
with those of sirolimus, trough levels were main-
Table 3. Most Frequent Adverse Events and Study-Related Serious Adverse 
Events.*
Event Adverse Events
Serious Adverse 
Events
Sirolimus
(N = 64)
Calcineurin 
Inhibitor 
(N = 56)
Sirolimus
(N = 64)
Calcineurin 
Inhibitor 
(N = 56)
number of patients
Edema 37† 16 0 0
Acne-like lesions 28 11 0 0
Aphthous ulcers 24‡ 0 0 0
Proteinuria 20 4 1 0
Diarrhea 17 6 6 1
Dyslipidemia 15 1 0 0
Pneumonitis 14§ 1 13 1
Anemia 12 6 0 0
Cough 10 1 0 0
Arthralgia 10 9 1 0
Worsening of hypertension 9 9 0 0
Leukopenia 7 2 0 0
Bronchitis 7 3 2 1
Urinary tract infection 7 4 4 0
Exercise dyspnea 6† 1 0 0
Unexplained fever 6 1 4 0
Herpes simplex 5 1 2 0
Rash 5¶ 0 2 0
Thrombocytopenia 5 1 0 0
Drug discontinuation because 
of any adverse event
15 8‖ 10 3
* Listed are all adverse events that were reported in at least 5 patients. The list-
ed adverse events include serious adverse events. A complete list of serious 
adverse events (as reported in 32 patients in the sirolimus group and 11 in 
the calcineurin-inhibitor group) is provided in Table S4 in the Supplementary 
Appendix. The listed events that were deemed to be related to a study drug 
were edema, acnelike lesions, aphthous ulcers, proteinuria, diarrhea, dyslipid-
emia, pneumonitis, anemia, cough, leukopenia, exercise dyspnea, unexplained 
fever, rash, and thrombocytopenia. Other uncommon study-related events 
listed in Table S4 were delayed healing, hyperglycemia, and hypokalemia.
† One patient discontinued sirolimus because of this event.
‡ Three patients discontinued sirolimus because of this event.
§ Seven patients discontinued sirolimus because of this event.
¶ Two patients discontinued sirolimus because of this event.
‖ Eight patients crossed over from the calcineurin-inhibitor group to receive si-
rolimus because of three serious adverse events (kidney cancer, lymphoma, 
and melanoma in one patient each) and new cutaneous squamous-cell carci-
noma (in five patients).
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tained within the study targets. Moreover, equiv-
alent doses of mycophenolate mofetil apparently 
induced higher drug exposure in patients treated 
with sirolimus than in those treated with cyclo-
sporine.24 Notably, we observed no events relat-
ed to an overreduction in immunosuppression 
(mainly rejection) in the sirolimus group.
The effects of mTOR inhibitors have been ex-
tensively studied in animal models and assessed 
in clinical studies both in patients who were not 
undergoing organ transplantation25,26 and in those 
with cancer. These drugs interrupt the PI3K–
AKT pathway, which plays a critical role in the 
regulation of cell proliferation, survival, mobility, 
and angiogenesis.14 Temsirolimus and everolimus 
are approved for the treatment of metastatic renal-
cell carcinoma,27,28 although at higher doses for 
everolimus than for the regimens routinely ad-
ministered after transplantation.29 In addition, 
mTOR inhibitors also inhibit the growth of en-
dothelial cells and the progression of tumor 
neovascularization at serum concentrations that 
correspond to the target levels for transplant 
recipients, both through a decrease of synthesis 
and a signaling inhibition of vascular endothe-
lial growth factor.9,14 The influence of immuno-
suppressive drugs on skin carcinogenesis induced 
by ultraviolet radiation (UV) has been assessed in 
mice. Larger tumors developed in animals that 
were treated with cyclosporine or tacrolimus than 
in those treated with sirolimus.30 Furthermore, 
sirolimus had a better effect on the progression 
of UV-induced tumors than on the initiation of 
such tumors.31 In transplant recipients, sirolimus 
has been shown to reduce the vascularization and 
thickness of cutaneous squamous-cell carcino-
mas.32 There is also evidence to suggest that skin 
carcinomas might be driven by infection with hu-
man papillomavirus.33 Since the E6 oncoprotein 
activates the mTOR1 pathway,34 we speculate 
that sirolimus might act on skin cancer through 
antiviral mechanisms that have been shown with 
other viruses, such as cytomegalovirus35-37 and 
human herpesvirus 8.38
In conclusion, in this study involving kidney-
transplant recipients with at least one previous 
cutaneous squamous-cell carcinoma, conversion 
from calcineurin inhibitors to sirolimus was asso-
ciated with a lower risk of subsequent skin cancers. 
The data suggest that the earlier the conversion 
occurs after an initial diagnosis of cutaneous 
squamous-cell carcinoma, the greater the efficacy.
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